Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Operating Leases (2023 - 2025)

Mangoceuticals' Operating Leases history spans 3 years, with the latest figure at $12167.0 for Q3 2025.

  • For Q3 2025, Operating Leases changed 0.0% year-over-year to $12167.0; the TTM value through Sep 2025 reached $12167.0, changed 0.0%, while the annual FY2024 figure was $64962.0, 0.0% changed from the prior year.
  • Operating Leases for Q3 2025 was $12167.0 at Mangoceuticals, down from $30117.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $143424.0 in Q3 2023 and bottomed at $12167.0 in Q3 2024.
  • The 3-year median for Operating Leases is $64961.0 (2023), against an average of $66323.0.
  • The largest YoY upside for Operating Leases was 0.0% in 2024 against a maximum downside of 91.52% in 2024.
  • A 3-year view of Operating Leases shows it stood at $64961.0 in 2023, then grew by 0.0% to $64962.0 in 2024, then plummeted by 81.27% to $12167.0 in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Operating Leases are $12167.0 (Q3 2025), $30117.0 (Q2 2025), and $47713.0 (Q1 2025).